You are here

Preliminary Results Announced From Phase III Onychomycosis Trials

CORONA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today preliminary results from two Phase III trials of its topical anti-fungal therapy for the treatment of onychomycosis, or nail fungus.

Two multi-center, double blind, randomized Phase III trials compared the safety, efficacy and tolerability of the topical anti-fungal treatment in 670 patients with toenail onychomycosis. Patients were randomized into one of two treatment groups: topical anti-fungal treatment or placebo. Topical anti-fungal patches were applied to the toenail on a daily basis for 12 months. Patients were evaluated at 6, 12, 15 and 18 months, following the start of treatment.

In one trial, the topical anti-fungal treatment achieved a statistically significant greater number of complete cures, as compared to placebo. Complete cure required success on three parameters: growth of a completely clear nail, negative fungal culture and a potassium hydroxide (KOH) test, negative for the physical presence of fungus. In the second trial, the topical anti-fungal treatment arm failed to demonstrate a statistically significant greater number of complete cures, as compared to placebo. Both trials showed the topical anti-fungal treatment to be well tolerated, with a low incidence of side effects.

Watson plans to complete and review the full data analysis over the next six to eight weeks to determine next steps for the program.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs